Effect and mechanism of endogenous metabolism on drug metabolism and disposition

doi:10.12092/j.issn.1009-2501.2019.05.016

Abstract

Abstract:

Endogenous substance metabolism is the response process of the body to internal and external factors at the level of cells, molecules, etc. It is the feedback of the body's own components on health, disease and foreign substances. Drug metabolism and disposition is a prerequisite for drugs to exert their effects and produce adverse reactions. Under different physiological or disease states, changes in the metabolism of endogenous substances will inevitably affect the drug metabolism, which will affect the efficacy and adverse reactions. Studies at home and abroad have shown that changes in the metabolism of endogenous substances can lead to changes in the content of certain intermediates or end products in the metabolic pathway, leading to changes in drug metabolizing enzymes and transporters. This article reviews the effects of endogenous glucose metabolism, lipid metabolism, nucleotide metabolism, amino acid metabolism and hormones on drug metabolism and its mechanisms, in order to provide reference and ideas for clinical safe medication and individualized treatment under different physiological and disease states.

Key words: endogenous substance metabolism, drug metabolism enzyme, transporter, clinical safe medication

CLC Number:

R969.1

CHEN Hongzhu, LIU Jianming, ZHOU Fang, JIA Yuanwei, WANG Guangji, ZHANG Jingwei. Effect and mechanism of endogenous metabolism on drug metabolism and disposition[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 580-588.

References

［1］Andreoli A, Garaci F, Cafarelli FP, et al. Body composition in clinical practice ［J］. Euro J Radiol, 2016, 85(8): 1461-1468.
［2］Dallmann A, Ince I, Coboeken K, et al. A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways ［J］. Clin Pharmacokinet, 2018, 57(6): 749-768.
［3］Elfaki I, Mir R, Almutairi FM, et al. Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis ［J］. Asian Pac J Cancer Prev, 2018, 19(8): 2057-2070.
［4］Wang W, Cai Q, Zhou F, et al. Impaired pentose phosphate pathway in the development of 3D MCF-7 cells mediated intracellular redox disturbance and multi-cellular resistance without drug induction ［J］. Red Biology, 2018, 15: 253-265.
［5］Fiorentino TV, Marini MA, Succurro E, et al. One-hour postload hyperglycemia: implications for prediction and prevention of type 2 diabetes ［J］. J Clin Endocrinol Metab, 2018, 103(9): 3131-3143.
［6］Chen F, Li DY, Zhang B, et al. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance ［J］? Drug Metab Rev, 2018, 50(3): 369-397.
［7］Kim YC,Lee AK,Lee JH,et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation ［J］. Eur J Pharm Sci, 2005, 26(1): 114-123.
［8］Matzke GR, Frye RF, Early JJ, et al. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity ［J］. Pharmacotherapy, 2000, 20(2): 182-190.
［9］Xu D, Li F, Zhang M, et al. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes ［J］. Acta Pharmacol Sinica, 2014, 35(9): 1215-1225.
［10］Jamwal R, De La Monte SM, Ogasawara K, et al. Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver ［J］. Mol Pharma, 2018, 15(7): 2621-2632.
［11］Shayakhmetova GM, Bondarenko LB, Matvienko AV, et al. Correlation between spermatogenesis disorders and rat testes CYP2E1 mRNA contents under experimental alcoholism or type I diabetes ［J］. Adv Med Sci, 2014, 59(2): 183-189.
［12］Natsumi K, Sakiko A, Jun U, et al. Increase in Pglycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes ［J］. Bio Biophy Acta, 2008, 1782(5): 355-360.
［13］Nowicki MT, Aleksunes LM, Sawant SP, et al. Renal and hepatic transporter expression in type 2 diabetic rats ［J］. Drug Metab Lett, 2008, 2(1): 11-17.
［14］Aoshima N, Fujie Y, Itoh T, et al. Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia ［J］. Sci Rep, 2014, 4: 6343.
［15］Cho S, Tripathi A, Chlipala G, et al. Fructose diet alleviates acetaminophen-induced hepatotoxicity in mice ［J］. PloS one, 2017, 12(8): e0182977.
［16］Sulis PM, Motta K, Barbosa AM, et al. Impact of fish oil supplementation and interruption of fructose ingestion on glucose and lipid homeostasis of rats drinking different concentrations of fructose ［J］. BioMed Res Int, 2017, 2017: 4378328.
［17］Guo Y, Cui JY, Lu H, et al. Effect of nine diets on mRNAs of phase-II conjugation enzymes in livers of mice ［J］. Xenobiotica, 2017, 47(8): 645-654.
［18］Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease ［J］. Nutrients, 2013, 5(8): 2901-2923.
［19］Kuan CY, Walker TH, Luo PG, et al. Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line ［J］. J Am Col Nutr, 2011, 30(4): 265-273.
［20］Gelsomino G, Corsetto PA, Campia I, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition ［J］. Mol Cancer, 2013, 12: 137.
［21］Palacharla RC, Uthukam V, Manoharan A, et al. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro-in vivo extrapolation of hepatic clearance ［J］. Euro J Pharma Scie, 2017, 101: 80-89.
［22］Okamura K, Ishii Y, Ikushiro S, et al. Fatty acyl-CoA as an endogenous activator of UDP-glucuronosyltransferases ［J］. Biochem Biophy Res Commu, 2006, 345(4): 1649-1656.
［23］Rezˇen T. The impact of cholesterol and its metabolites on drug metabolism ［J］. Expert Opin Drug Metab Toxicol, 2011, 7(4): 387-398.
［24］Junica J, Dovrtělová G, Nosková K, et al. Bile acids, nuclear receptors and cytochrome P450 ［J］. Physiol Res, 2016, 21(65): S427-S40.
［25］Yamada A,Shimizu N,Hikima T,et al.Effect of cholesterol on the interaction of cytochrome P450 substrate drug chlorzoxazone with the phosphatidylcholine bilayer［J］.Biochemistry,2016,55(28):3888-3898.
［26］Takano M, Higashi M, Ito H, et al. Functional expression of breast cancer resistance protein and cholesterol effect in humanerythrocyte membranes ［J］. Pharmazie, 2018, 73(12): 700-705.
［27］Causevic-ramosevac A,Semiz S.Drug interactions with statins［J］.Acta pharmaceutica,2013,63(3):277-293.
［28］Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation ［J］. Am J Kidney Dis, 2018, 71(6): 851-865.
［29］Huo X, Liu K. Renal organic anion transporters in drug-drug interactions and diseases ［J］. Eur J Pharm Sci, 2018, 112: 8-19.
［30］Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia ［J］. Nat Comm, 2012, 3: 764.
［31］Dankers AC, Mutsaers HA, Dijkman HB, et al. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP) ［J］. Biochim Biophys Acta, 2013, 1832(10): 1715-1722.
［32］Luna-munguia H,Salvamoser JD,Pascher B,et al.Glutamate-mediated upregulation of the multidrug resistance protein 2 in porcine and human brain capillaries［J］.J Pharmacol Exp Thera,2015,352(2):368-378.
［33］Salvamoser JD, Avemary J, Luna-munguia H, et al. Glutamate-mediated down-regulation of the multidrug-resistance protein BCRP/ABCG2 in porcine and human brain capillaries ［J］. Mol Pharm, 2015, 12(6): 2049-2060.
［34］Watanabe M, Tateishi T, Asoh M, et al. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats ［J］. Life Sci, 1998, 63(19): 1685-1692.
［35］Zimmermann C, Van Waterschoot RA, Harmsen S, et al. PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide ［J］. Eur J Pharm Sci, 2009, 36(4/5): 565-571.
［36］Maier A,Zimmermann C,Beglinger C,et al.Effects of budesonide on P-glycoprotein expression in intestinal cell lines［J］.Brit J Pharmacol,2007,150(3):361-368.
［37］Chen N, Cui D, Wang Q, et al. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes ［J］. Xenobiotica, 2018, 48(6): 637-646.
［38］Zhang Z,Farooq M,Prasad B,et al.Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes［J］.Drug Metab Dispos,2015,43(6):836-842.
［39］Cizkova K, Tauber Z. Time-dependent expression pattern of cytochrome P450 epoxygenases and soluble epoxide hydrolase in normal human placenta ［J］. Acta Histochemica, 2018, 120(6): 513-519.
［40］Pan X, Ning M, Jeong H. Transcriptional regulation of CYP2D6 expression ［J］. Drug Metab Dispos, 2017, 45(1): 42-48.
［41］Chikada H, Ida K, Ando E, et al. Establishment and analysis of a mouse model that regulates sex-related differences in liver drug metabolism ［J］. Lab Invest, 2018, 98(11): 1500-1511.
［42］Chen DW, Du Z, Zhang CZ, et al. The inhibition of UDP-glucuronosyltransferases (UGTs) by tetraiodothyronine (T4) and triiodothyronine (T3) ［J］. Xenobiotica, 2018, 48(3): 250-257.
［43］Liddle C,Goodwin BJ,George JCL,et al. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes ［J］. J Clin Endocrinol Metab, 1998, 83(7): 2411-2416.
［44］Takahashi N, Inui N, Morita H, et al. Effect of thyroid hormone on the activity of CYP3A enzyme in humans ［J］. J Clin Pharmacol, 2010, 50(1): 88-93.
［45］Nishio N,Katsura T,Inui K.Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells［J］.Pharm Res,2008,25(5):1037-1042.
［46］Ishii Y,Nurrochmad A,Yamada H.Modulation of UDP-glucuronosyltransferase activity by endogenous compounds［J］.Drug Metab Pharm,2010,25(2):134-148.
［47］Shepherd SR, Baird SJ, Hallinan T, et al. An investigation of the transverse topology of bilirubin UDP glucuronosyltransferase in rat hepatic endoplasmic reticulum ［J］. Biochem J 1989, 259(2): 617-620.
［48］Wang Z, Long H, Chang C, et al. Crosstalk between metabolism and epigenetic modifications in autoimmune diseases: a comprehensive overview ［J］. Cell Mol Life Sci, 2018, 75(18): 3353-3369.
［49］Beedanagari SR, Taylor RT, Bui P, et al. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes ［J］. Mol Pharmacol, 2010, 78(4): 608-616.
［50］Simithy J, Sidoli S, Yuan ZF, et al. Characterization of histone acylations links chromatin modifications with metabolism ［J］. Nat Comm, 2017, 8(1): 1141.
［51］Wu Y, Shi X, Liu Y, et al. Histone deacetylase 1 is required for carbamazepine-induced CYP3A4 expression ［J］. J Pharm Biomed Anal, 2012, 58: 78-82.
［52］Gulliver LS.Xenobiotics and the glucocorticoid receptor［J］.Toxicol Applied Pharmacol,2017,319:69-79.
［53］Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair ［J］. Trends Endocrinol Metab, 2008, 19(9): 331-339.
［54］Ghosh C,Hossain M,Solanki J,et al.Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells［J］.Epilepsia,2017,58(4):576-585.
［55］RadimV, Lucie S, Katalin M, et al. Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes ［J］. Chem Biol Interact, 2009, 179(2/3): 288-296.
［56］Das RK, Banerjee S, Shapiro BH. Growth hormone: a newly identified developmental organizer ［J］. J Endocrinol, 2017, 232(3): 377-389.
［57］Lamba V,Jia B,Liang F.STAT5A and STAT5B have opposite correlations with drug response gene expression［J］.Bioch Biophy Res Comm,2016,479(2):117-124.
［58］Wojcikowski J, Daniel WA. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat ［J］. Expert Opin Drug Metab Toxicol, 2009, 5(6): 631-645.
［59］Bromek E, Rysz M, Haduch A, et al. Serotonin receptors of 5-HT2 type in the hypothalamic arcuate nuclei positively regulate liver cytochrome P450 via stimulation of the growth hormone-releasing hormone/growth hormone hormonal pathway ［J］. Drug Metab Dispos, 2019, 47(2): 80-85.
［60］Hunter J, Kassam A, Winrow CJ, et al. Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes ［J］. Mol Cell Endocrinol, 1996, 116(2): 213-221.
［61］Vrzal R, Vrzalova A, Grycova A, et al. Activated thyroid hormone receptor modulates dioxin-inducible aryl hydrocarbon receptor-mediated CYP1A1 induction in human hepatocytes but not in human hepatocarcinoma HepG2 cells ［J］. Toxicol Lett, 2017, 275: 77-82.
［62］Cheung C, Akiyama TE, Kudo G, et al. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice ［J］. Biochem Pharmacol, 2003, 66(10): 2011-2020.
［63］Deprez J, Bertrand L, Alessi DR, et al. Partial purification and characterization of a wortmannin-sensitive and insulin-stimulated protein kinase that activates heart 6-phosphofructo-2-kinase ［J］. Biochem J, 2000, 347(1): 305-312.
［64］Harkitis P, Daskalopoulos EP, Malliou F, et al. Dopamine D2-receptor antagonists down-regulate CYP1A1/2 and CYP1B1 in the rat liver ［J］. PloS one, 2015, 10(10): e0128708.
［65］孙宏斌. 代谢性炎症相关疾病的药物干预［J］. 药学进展, 2017, 41(10): 721-726.
［66］Wu D, Li W, Lok P, et al. AhR deficiency impairs expression of LPS-induced inflammatory genes in mice ［J］. Biochem Biophys Res Commun, 2011, 410(2): 358-363.
［67］Kusunoki Y, Ikarashi N, Hayakawa Y, et al. Hepatic early inflammation induces downregulation of hepatic cytochrome P450 expression and metabolic activity in the dextran sulfate sodium-induced murine colitis ［J］. Euro J Pharma Sci, 2014, 54: 17-27.
［68］He L,Li H,Huang N,et al.Alpha-ketoglutarate suppresses the NF-κB-mediated inflammatory pathway and enhances the PXR-regulated detoxification pathway［J］.Oncotarget,2017,8(61):102974-102988.
［69］叶容芳, 熊玉卿. 微小RNA对核受体调控药物代谢酶和转运体的研究现状［J］. 中国临床药理学杂志, 2018, 34(1): 85-91.
［70］阳喜定, 阳国平, 黄洁, 等. NF-κB对细胞色素P450调控作用机制研究进展［J］. 中国临床药理学与治疗学, 2015, 20(11): 1302-1307.
［71］Vachirayonsti T, Ho KW, Yang D, et al. Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4alpha and up-regulating liver-enriched inhibitory protein ［J］. Toxicol Sciences, 2015, 144(2): 382-392.
［72］Yu AM, Tian Y, Tu MJ, et al. MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy［J］. Drug Metab Dispos, 2016, 44(3): 308-319.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[3]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[4]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[5]	LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
[6]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[7]	ZHOU Han, LIU Xiaodong. Application of physiologically based pharmacokinetic model in drug development and several questions being thought [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
[8]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[9]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[10]	ZHONG Kailong, WANG Yongsheng, CHEN Fang, YE Yanrong. Exploration and expectation on treatment strategies of central nervous system diseases based on transporters at blood-brain barrier [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 953-960.
[11]	LI Danyun, NIU Peiguang, SHI Daohua. Advances in antitumor drugs based on glutamine metabolism#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 810-816.
[12]	SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng. Methods and progress of clinical research on drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045.
[13]	LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909.
[14]	SHAN Xiaolei, FU Shujun, GAO Guanghua, SUN Tao, WANG Qingli, YU Shanshan. Metabolism- and transporter-mediated drug-drug interaction-overview of in vitro study and cases analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1165-1171.
[15]	ZHANG Jingxian, CHEN Tao, ZHANG Xiangqi, SHI Meizhi, CHEN Junjun, ZHANG Kezhi, YANG Jiao, GUO Cheng, WANG Laiyou, HAN Yonglong. Inhibition effects of Danhong injection on three transporters in human primary hepatocytes in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 389-394.